Financial Performance - ORIC Pharmaceuticals reported a net loss of $30.5 million for Q4 2025, compared to a net loss of $36.3 million in Q4 2024, reflecting a decrease of 16% year-over-year[15]. - Research and development (R&D) expenses for Q4 2025 were $25.9 million, down from $32.0 million in Q4 2024, a decrease of 19.5%[7]. - General and administrative (G&A) expenses increased to $8.7 million in Q4 2025 from $7.6 million in Q4 2024, a rise of 14.5%[7]. - Cash, cash equivalents, and investments totaled $392.3 million as of December 31, 2025, with an expected runway into the second half of 2028[7]. - Total assets increased to $408.9 million as of December 31, 2025, compared to $274.1 million in 2024, reflecting a growth of 49%[13]. Clinical Development - Rinzimetostat demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate in mCRPC patients, with 76% achieving over 50% ctDNA reduction[5]. - Enozertinib showed a 67% overall response rate (ORR) in EGFR exon 20 NSCLC patients and a 100% intracranial ORR in patients with measurable CNS disease[5]. - ORIC anticipates initiating its first global Phase 3 registrational trial for rinzimetostat in mCRPC in the first half of 2026[6]. - The company expects multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential registrational trials[1]. Funding and Financial Position - The company raised $264 million from healthcare specialist funds, enhancing its financial position for future clinical trials[1].

Exhibit 99.1 News Release Allison Transmission Announces Fourth Quarter and Full Year 2025 Results INDIANAPOLIS, February 23, 2026 – Allison Transmission Holdings Inc. (NYSE: ALSN) today reported full year 2025 net sales of $3 billion with Adjusted EBITDA margin of 37.5 percent and net cash provided by operating activities of $836 million. David S. Graziosi, Chair, President and Chief Executive Officer of Allison commented, "Although 2025 presented meaningful macroeconomic challenges, we remained discipline ...

Financial Performance - For the year ended December 31, 2025, total operating expenses increased to $1,094.4 million, up from $226.0 million in 2024, representing a change of $868.4 million [489]. - The net loss for the year ended December 31, 2025, was $1,079.6 million, compared to a net loss of $221.3 million in 2024, marking an increase of $858.3 million [489]. - The company incurred a net loss of $1,079.6 million for the year ended December 31, 2025, with cash flows used in operating activities amounting to $322.9 million [503]. Operating Expenses - Research and development expenses rose significantly to $537.7 million in 2025 from $150.8 million in 2024, an increase of $386.9 million [489]. - General and administrative expenses surged to $556.7 million in 2025, compared to $60.2 million in 2024, reflecting a $496.5 million increase [489]. - Stock-based compensation expenses increased dramatically to $218.6 million in 2025 from $16.0 million in 2024, a rise of $202.6 million [491]. - Research and development expenses increased by $371.9 million for the year ended December 31, 2025, compared to the prior year, driven by a $202.6 million increase in stock-based compensation and a $165.5 million increase in oncology-related expenses for ivonescimab [493]. - General and administrative expenses rose by $496.5 million for the year ended December 31, 2025, primarily due to a $478.8 million increase in stock-based compensation [496]. - The company expects to incur significant expenses and increasing operating losses for the foreseeable future, particularly related to the development of ivonescimab [502]. - The company anticipates ongoing increases in general and administrative expenses as it scales its infrastructure to support the development of ivonescimab [496]. Clinical Trials and Research - The company completed enrollment in its HARMONi clinical trial in October 2024 and announced topline results in May 2025, showing a median progression-free survival (PFS) of 6.8 months for ivonescimab plus chemotherapy compared to 4.4 months for chemotherapy alone [472]. - The hazard ratio for PFS in the primary analysis was 0.52 (95% CI: 0.41 – 0.66; p<0.00001), indicating a statistically significant improvement [472]. - An additional ad hoc overall survival (OS) analysis in September 2025 showed a hazard ratio of 0.78 (95% CI: 0.62 – 0.98; nominal p=0.0332) for Western patients, with median OS of 17.0 months for ivonescimab compared to 14.0 months for placebo [476]. - The company submitted a Biologics License Application (BLA) in Q4 2025 for ivonescimab plus chemotherapy, with the FDA accepting the filing in January 2026 [478]. Cash Flow and Financing - Cash and cash equivalents, along with short-term investments, totaled $713.4 million as of December 31, 2025, providing sufficient cash to fund operating needs for at least the next 12 months [504]. - Net cash provided by financing activities for the year ended December 31, 2025, was $617.5 million, primarily from a private placement of $500.0 million [518]. - The company raised gross proceeds of $150.7 million from its ATM Agreement since inception, contributing to its liquidity [501]. - Net cash provided by financing activities for the year ended December 31, 2024 was $381.2 million, primarily due to $434.9 million from private placements and $43.0 million from the current ATM Agreement [519]. Commitments and Obligations - As of December 31, 2025, total unconditional purchase obligations, excluding lease commitments, are estimated to be approximately $18.0 million [527]. - The company has estimated lease commitments totaling $27.3 million as of December 31, 2025, with $3.5 million due within one year [521]. - The company has no capital commitments as of December 31, 2025 [520]. Debt and Notes - The Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025, with interest accruing at a minimum of 12% [525]. - The company repaid the $20 million Zanganeh Note on February 15, 2023, and the $400 million Duggan Promissory Note was also repaid using proceeds from the 2023 Rights Offering [524]. - The company entered into a Note Purchase Agreement for $520 million in bridge financing through three unsecured promissory notes [530]. - The company accrued cash interest of $7.3 million on the Duggan September Note, which was fully repaid on October 1, 2024 [526]. Tax Positions - The Company recorded unrecognized tax positions of $3.9 million, $2.1 million, and $1.1 million for the years ending December 31, 2025, 2024, and 2023, respectively [542]. - The Company has a full valuation allowance against deferred tax assets exceeding deferred tax liabilities, indicating that future tax benefits are unlikely to be realized [541]. - The Company has $0.9 million of outstanding research and development tax credits as of December 31, 2025, which are expected to be collected based on historical collection rates [549]. Risk Management - The Company is exposed to foreign currency exchange rate risk, particularly with the pound sterling and euro, but currently does not consider the impact material [547]. - The Company maintains a portfolio of cash, cash equivalents, and short-term investments to minimize interest rate risk, with no material exposure to changes in fair value due to interest rate fluctuations [548]. - The Company considers all material counterparties to be creditworthy, indicating low credit risk across its operations [549]. Stock Options and Dividends - The Company uses a Monte Carlo simulation model to estimate the fair value of stock options, with key assumptions including risk-free interest rates and stock price volatility [538]. - Stock option awards generally vest over terms of 3 or 4 years, and the Company estimates expected forfeitures at the time of grant [539]. - The Company has not paid and does not intend to pay dividends, reflecting its focus on reinvestment rather than shareholder payouts [544].

Exhibit 99.1 MEDIAALPHA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Fourth Quarter Revenue of $291 million and Record Transaction Value of $613 million; Record Transaction Value of $552 million in Property & Casualty Insurance Vertical Record Full-Year 2025 Revenue of $1.1 billion and Transaction Value of $2.2 billion Record Full-Year 2025 Net Income of $26.8 million and Adjusted EBITDA of $113.7 million (1) Board of Directors Doubles Share Repurchase Authorization to $100 million Los Ange ...

ACV Announces Fourth Quarter and Full-Year 2025 Results 15% Revenue Growth and Adjusted EBITDA Exceeding High-End of Guidance Full-Year 2025 Highlights First Quarter and Full-Year 2026 Guidance BUFFALO, February 23, 2026 — ACV (NYSE: ACVA), a leading digital automotive marketplace and data services partner for dealers and commercial clients, today reported results for its fourth quarter and full-year ended December 31, 2025. "We are very pleased with our fourth quarter results, with revenue at the high-end ...

Financial Performance - Keysight Technologies reported record revenue of $1.60 billion for Q1 2026, a 23% increase from $1.30 billion in Q1 2025[5] - Non-GAAP net income for Q1 2026 was $376 million, or $2.17 per share, compared to $317 million, or $1.82 per share in Q1 2025[5] - The company reported a GAAP net income of $281 million, or $1.63 per share, compared to $169 million, or $0.97 per share in Q1 2025[5] - GAAP net income for Q1 2026 was $281 million, with diluted EPS of $1.63, compared to $169 million and $0.97 in Q1 2025, representing a 66% increase in net income[21] - Non-GAAP net income for Q1 2026 was $376 million, with diluted EPS of $2.17, up from $317 million and $1.82 in Q1 2025, reflecting a 18.6% increase in net income[21] - Total revenue for Q1 2026 was $1,600 million, a 23% increase from $1,298 million in Q1 2025[30] Revenue Breakdown - The Communications Solutions Group (CSG) generated $1,124 million in revenue, reflecting a 27% year-over-year growth, with commercial communications up 33% and aerospace, defense, and government up 18%[3] - Revenue for the Communications Solutions Group increased by 27% to $1,124 million in Q1 2026, compared to $883 million in Q1 2025[24] - Revenue for the Electronic Industrial Solutions Group rose by 15% to $476 million in Q1 2026, up from $415 million in Q1 2025[25] - Revenue from Aerospace, Defense and Government increased by 18% to $366 million in Q1 2026, compared to $311 million in Q1 2025[30] - Revenue from Commercial Communications surged by 33% to $758 million in Q1 2026, up from $572 million in Q1 2025[30] Cash Flow and Assets - Cash flow from operations was $441 million, up from $378 million in the same quarter last year[5] - Free cash flow for Q1 2026 was $407 million, compared to $346 million in Q1 2025, indicating a 17.6% increase[27] - As of January 31, 2026, Keysight's cash, cash equivalents, and restricted cash totaled $2.20 billion[5] - Total assets increased to $11.481 billion as of January 31, 2026, compared to $11.301 billion at the end of October 2025[17] Future Projections - Keysight expects Q2 2026 revenue to be between $1.690 billion and $1.710 billion, representing approximately 30% year-over-year growth[4] - Non-GAAP earnings per share for Q2 2026 are projected to be between $2.27 and $2.33, based on approximately 173 million diluted shares[4] Gross Margin - The gross margin for the Communications Solutions Group remained stable at 68% for both Q1 2026 and Q1 2025[24] - The gross margin for the Electronic Industrial Solutions Group improved slightly to 62% in Q1 2026 from 61% in Q1 2025[25] Group Performance - The Electronic Industrial Solutions Group (EISG) achieved $476 million in revenue, a 15% increase from the previous year, driven by double-digit growth across automotive, energy, general electronics, and semiconductor markets[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 27, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to_______ Commission file number 1-35166 Fortune Brands Innovations, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorpora ...

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements Generated full-year 2025 net product sales of XDEMVY of $451.4 million, an increase of more than 150% year-over-year ® Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference ca ...

Exhibit 99.1 Backblaze Announces Fourth Quarter and Full Year 2025 Financial Results 24% Revenue Growth in B2 Cloud Storage, 12% Revenue Growth Overall in Q4 2025 San Mateo, CA (February 23, 2026)—Backblaze, Inc. (Nasdaq: BLZE), the high-performance cloud storage platform for the AI era, today announced results for its fourth quarter ended December 31, 2025. "In Q4, we closed our first eight-figure TCV neocloud agreement," said Gleb Budman, co-founder and CEO of Backblaze. "This marks yet another neocloud w ...

Revenue Performance - Revenue for 2025 was approximately $2.35 billion, representing a 59% year-over-year increase[1] - U.S. revenue for 2025 was $2.21 billion, a 53% increase from 2024[4] - Revenue from the Rest of the World for 2025 was $134 million, a 399% increase from 2024[4] - Total revenue for the year ended December 31, 2025, was $2,347,637,000, a 59% increase from $1,476,514,000 in 2024[30] - Revenue for 2025 was $2,347,637, compared to $1,476,514 in 2024, reflecting a growth of 58.7%[39] Profitability Metrics - Net income for 2025 was $128 million, with Adjusted EBITDA of $318 million[1] - Net income for the year ended December 31, 2025, was $128,365,000, slightly up from $126,038,000 in 2024[30] - Adjusted EBITDA for 2025 reached $317,984, up from $176,873 in 2024, indicating an increase of 79.8%[39] - The Adjusted EBITDA margin for 2025 was 14%, compared to 12% in 2024, indicating improved operational efficiency[39] Subscriber Growth - Subscribers grew to over 2.5 million, marking a 13% increase year-over-year[1] - Monthly revenue per average subscriber increased by 28% year-over-year to $83 for 2025[3] Financial Guidance - Q1 2026 revenue guidance is projected between $600 million and $625 million, with Adjusted EBITDA expected to be between $35 million and $55 million[15] - Full year 2026 revenue guidance is estimated to be in the range of $2.7 billion to $2.9 billion, with Adjusted EBITDA between $300 million and $375 million[15] Cash Flow and Liquidity - Free Cash Flow for 2025 was $57.4 million, a decrease from $198.3 million in 2024[7] - Net cash provided by operating activities for 2025 was $300,006, an increase from $251,084 in 2024, showing a growth of 19.5%[41] - Free Cash Flow for 2025 was $(57,415), a decrease from $198,334 in 2024, indicating a decline in liquidity[41] Expenses and Costs - Operating expenses for the year ended December 31, 2025, totaled $1,627,765,000, compared to $1,111,232,000 in 2024, reflecting a significant increase in marketing and operational costs[30] - Marketing expenses for the year ended December 31, 2025, were $919,296,000, up from $678,844,000 in 2024, indicating a strategic focus on brand growth[30] Asset and Liability Overview - The company reported a total of $767,638,000 in current assets as of December 31, 2025, compared to $395,831,000 in 2024[28] - Total liabilities increased to $1,613,777,000 as of December 31, 2025, from $230,823,000 in 2024[28] Strategic Changes - The company plans to discontinue reporting Online Revenue and Wholesale Revenue starting March 31, 2026, focusing instead on United States Revenue and Rest of the World Revenue[21] - Monthly Revenue per Average Subscriber will replace Monthly Online Revenue per Average Subscriber in future reports, reflecting a shift in business metrics[21] - The company is expanding internationally, including operations in the European Union and Canada, and plans to acquire Eucalyptus[21] Stock and Investment Activities - Stock-based compensation for 2025 was $135,244, significantly higher than $92,322 in 2024, marking an increase of 46.5%[39] - The company reported a net cash used in investing activities of $(1,024,958) for 2025, a significant increase from $(19,048) in 2024[32] - The company issued $970,000 in convertible senior notes in 2025, contributing to financing activities[32]